Immunoglobulin G Fc engineering for localized therapy: Eliminating neonatal Fc receptor interactions and ensuring purification using protein A
Protein Science · 2025
DOI: 10.1002/pro.70351 ↗Kurz gefasst
Fachartikel in der Zeitschrift Protein Science, 2025. Verfasst von Akifumi Kato und 7 weiteren Autor:innen. Beteiligte Einrichtung: Innovation Center, Research Division, Kyowa Kirin Co., Ltd, Tokyo, Japan. Hauptthemen laut MEDLINE: Receptors, Fc, Histocompatibility Antigens Class I, Immunoglobulin G, Protein Engineering. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Monoclonal antibodies (mAbs) and bispecific antibodies (bsAbs) have transformed therapeutic strategies for various diseases. However, administering them can lead to unwanted adverse effects and insufficient delivery to local disease sites. Recent research has shown that substitutions in the immunoglobulin G (IgG) Fc region, designed to eliminate binding to the neonatal Fc receptor (FcRn), which accelerates clearance from systemic circulation, may improve the safety of antibody therapies intended for localized use. A major concern with these substitutions is their ability to impair binding to protein A, which is considered the gold standard for large‐scale antibody purification. In this study, we investigated multiple amino acid substitutions at residues I253, H310, H435, and Y436—positions known to affect FcRn or protein A interactions—and found that H435F eliminates FcRn binding while maintaining protein A affinity. Importantly, the H435F substitution resulted in accelerated clearance and a shorter serum half‐life in human FcRn transgenic mice. Moreover, purification using protein A chromatography proved to be effective without significantly compromising yield. Overall, these findings highlight the potential of the H435F substitution to optimize the pharmacokinetics of antibody therapeutics for localized use, reducing systemic side effects. This study paves the way for the use of antibody‐based therapeutics in localized treatments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Innovation Center, Research Division, Kyowa Kirin Co., Ltd, Tokyo, Japan.
- Bio-Pharmaceutical Center, Research Division, Kyowa Kirin Co. Ltd, Shizuoka, Japan.
- Bio-Pharmaceutical Center, Research Division, Kyowa Kirin Co. Ltd, Tokyo, Japan.
- Intellectual Property Department, Kyowa Kirin Co., Ltd, Tokyo, Japan.
- Research Planning Department, Research Division, Kyowa Kirin Co., Ltd, Tokyo, Japan.
ORCID-Profile: Akifumi Kato
Zitieren
APA
Kato, A., Toshima, A., Takekawa, G., Miyagi, H., Kubota, A., Hori, S., Uemura, Y., & Niwa, R. (2025). Immunoglobulin G Fc engineering for localized therapy: Eliminating neonatal Fc receptor interactions and ensuring purification using protein A. Protein Science. https://doi.org/10.1002/pro.70351
Vancouver
Kato A, Toshima A, Takekawa G, Miyagi H, Kubota A, Hori S, et al. Immunoglobulin G Fc engineering for localized therapy: Eliminating neonatal Fc receptor interactions and ensuring purification using protein A. Protein Science. 2025. doi:10.1002/pro.70351
BibTeX
@article{Kato2025,
author = {Kato, Akifumi and Toshima, Asami and Takekawa, Gennosuke and Miyagi, Hikaru and Kubota, Ai and Hori, Sayaka and Uemura, Yasunori and Niwa, Rinpei},
title = {Immunoglobulin G Fc engineering for localized therapy: Eliminating neonatal Fc receptor interactions and ensuring purification using protein A},
journal = {Protein Science},
year = {2025},
doi = {10.1002/pro.70351}
}
EUVIMED